Revised Outcome of Board Meeting held on 26th May, 2025 for Audited Financial Result for the Quarter and Year ended 31st March, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bacil Pharma's board approved its audited financial results for FY25, which is a revised submission of an earlier board meeting outcome. The company reported zero revenue from operations for FY25, with total income of Rs 66.14 lakhs coming entirely from other income (interest/dividends), compared to Rs 13.05 lakhs in FY24. Profit after tax swung to Rs 40.41 lakhs from a loss of Rs 5.91 lakhs in FY24, lifting EPS to Rs 0.64 from Rs (0.10). The company raised Rs 276 lakhs during the year via a preferential allotment of 74.43 lakh equity shares, more than doubling its paid-up capital to Rs 1,397 lakhs. Cash and investments surged to Rs 2,421 lakhs from Rs 65 lakhs a year earlier, while borrowings remain negligible at Rs 16.39 lakhs.
The headline profit turnaround is driven purely by investment income, not any operating business, so shareholders should not read this as operational recovery. The auditor flagged an Emphasis of Matter regarding outstanding loans and advances to parties whose recoverability could not be confirmed — a credit risk red flag worth monitoring.